

A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration

Lesley Pahs, PharmD*; Chris Droege, PharmD; Hilary Kneale, DO; Arthur Pancioli, MD

*Corresponding Author. E-mail: lpahs@hotmail.com.

Orolingual angioedema is a rare adverse effect of tissue plasminogen activator (tPA), with an incidence of 1% to 5%. There are currently no published reports describing resolution of tPA-induced orolingual angioedema with complement inhibitor therapy. A 72-year-old man receiving home angiotensin-converting enzyme inhibitor therapy presented to the emergency department with newly developed orolingual angioedema after treatment with tPA for acute ischemic stroke. Therapy was initiated with intravenous methylprednisolone 125 mg, famotidine 20 mg, and diphenhydramine 50 mg, without significant improvement. Because of increased concern for airway protection, plasma-derived C1 esterase inhibitor was administered. Concerns about progressive and airway-threatening orolingual angioedema subsided 2 hours after administration, and invasive airway maneuvers were avoided. Orolingual angioedema is an infrequent, severe adverse effect of tPA for treatment of acute ischemic stroke. Complement inhibitors may be an additional therapeutic option for patients presenting with orolingual angioedema with potential airway compromise that is refractory to standard anaphylactic therapies. [Ann Emerg Med. 2016;■:1-4.]

0196-0644/\$-see front matter

Copyright © 2016 by the American College of Emergency Physicians.

<http://dx.doi.org/10.1016/j.annemergmed.2016.02.019>

INTRODUCTION

Orolingual angioedema can be a life-threatening crisis initiated by genetic factors or by certain foods, medications, infections, or stress. Hereditary angioedema has edematous and inflammatory consequences similar to those of other causes, but it is due to qualitative or quantitative dysfunction of C1 esterase inhibitor.^{1,2} This can result in excessive release of bradykinin and histamine, leading to increased vascular permeability and edema. Icatibant, ecallantide, and plasma-derived C1 esterase inhibitor are approved hereditary angioedema treatments that target areas to prevent and reverse orolingual angioedema.

Orolingual angioedema is a rare adverse effect of tissue plasminogen activator (tPA) treatment of acute ischemic stroke, with a reported incidence of between 1% and 5%.³⁻¹⁰ The frontal, insular, and peri-insular regions are often involved and are believed to play a role in the pathophysiology of stroke-associated angioedema. This association is thought to be due to proximity to the facial cortex, in conjunction with increased sympathetic tone and peripheral vasoconstriction, leading to cerebral dysregulation.^{10,11} Orolingual angioedema developing after tPA administration for acute ischemic stroke may manifest as unilateral swelling of the lips, tongue, and face. The resultant edema is commonly contralateral to the ischemic lesion, which is believed to be due to the infarction's triggering autonomic dysfunction and vasomotor changes in the hemiparetic side.¹⁰ Despite this distinct presentation,

available literature has demonstrated equal representation of bilateral, contralateral, and ipsilateral edema.^{5,7,11}

The proposed mechanism of tPA-induced orolingual angioedema is shown in Figure 1.^{1,6,7,9,11} Plasminogen is activated to plasmin by tPA, which leads to fibrinolysis and activation of the complement cascade and kinin pathway. Complement cascade activation causes anaphylotoxin release, which results in bradykinin production and vasodilatation. Patients receiving angiotensin-converting enzyme inhibitors who also receive tPA may be at higher risk for angioedema.^{3,4,7,10} Angiotensin-converting enzyme inhibitors block plasma kinases responsible for bradykinin inactivation, resulting in elevated baseline bradykinin concentrations. Complement activation, histamine release, and bradykinin release are believed to be the primary mediators of tPA-associated angioedema.^{1,2,5-7,9-13} Given a lack of direct treatment for tPA-induced orolingual angioedema, the current treatment recommendations suggest supportive care, corticosteroids, epinephrine, and histamine antagonists.^{3-5,7,9} There is potential to use hereditary angioedema therapies in patients presenting with tPA-induced orolingual angioedema refractory to the first-line therapies.

CASE REPORT

A 72-year-old white man with a history of coronary artery disease, myocardial infarction requiring 2 drug-eluting stents, hypertension, and hyperlipidemia presented




Figure 1. Mechanism of reaction. Potential treatment sites (dashed lines) are targeted throughout the cascade with histamine receptor blockers (famotidine and diphenhydramine), kallikrein inhibition (ecallantide [Kalbitor]), and bradykinin B2 competitive inhibition (icatibant [Firazyr]) and C1 esterase inhibition (C1 esterase inhibitor [Berinert]). The association with angiotensin-converting enzyme inhibitor occurs because of the inhibition of plasma kinases, which typically inactivate bradykinin. ACE, Angiotensin-converting enzyme. (Adapted with permission from Zarar et al,⁹ Maertins et al,¹³ and Lipski et al.¹⁷)

with sudden-onset right-sided weakness, dysarthria, and a National Institutes of Health Stroke Scale score of 10. Formal medication reconciliation was performed and included atenolol 25 mg, lisinopril 20 mg, hydrochlorothiazide 12.5 mg, atorvastatin 80 mg, aspirin 81 mg, and vitamin supplements. The patient received a diagnosis of acute ischemic stroke and also received intravenous tPA. Approximately 2 hours after tPA initiation, the patient developed tongue swelling and received diphenhydramine 25 mg intravenously during transfer to the comprehensive stroke center.

The patient was noted to have progressively worsening orolingual angioedema in transfer to the ICU but displayed improvement of right-sided weakness. He received methylprednisolone 125 mg, famotidine 20 mg, and diphenhydramine 50 mg intravenously within 5 minutes of presentation for symptomatic treatment of orolingual angioedema. Epinephrine was not administered at this time per prescriber discretion. Because of progressive tongue swelling, airway compromise, and the potential of a difficult airway in the context of recent thrombolysis, the interdisciplinary team decided to administer plasma-derived C1 esterase inhibitor for treatment of orolingual angioedema. Before and after administration of the plasma-derived C1 esterase inhibitor, values correlating with the complement cascade were evaluated by the on-site clinical

laboratory. Plasma-derived C1 esterase inhibitor was administered within 2 hours of ICU arrival at 1,500 IU (20 IU/kg, rounded to the nearest vial size), with laboratory values evaluated pre- and posttherapy to assess biomarker response. C1 esterase inhibitor, C1 esterase inhibitor function, C4 binding protein, C4 complement, and tryptase were assessed to ensure that the C1 esterase inhibitor was not low in value or function, to evaluate whether levels further downstream in the cascade decreased after administration of the drug, and to observe the extent of mast cell degradation by using tryptase levels. All laboratory values were within normal ranges. No standardized plan was devised for these values to influence acute management or additional dosing because these were addressed by physical examination. Two hours after plasma-derived C1 esterase inhibitor administration, swelling associated with the orolingual angioedema began to visually improve per physical evaluation every 15 minutes. Potentially intubation or cricothyroidotomy were avoided (Figure 2).

The patient developed bilateral posterior parietal lobe intraparenchymal hemorrhages recognized by a clinical decline 6 hours after tPA was administered; this adverse effect has previously been described and was thought to be related to the tPA.¹⁴ The patient developed malignant cerebral edema that the clinical team believed was related to either the stroke or the hemorrhage. No existing



Figure 2. Pre- and post-treatment with the C1 esterase inhibitor. The patient's tongue occupies most of his mouth and he is unable to retract his tongue (left). Posttreatment, the patient is able to retract his tongue fully into his mouth, although slight swelling is still evident (right).

mechanism or previous reports for C1 esterase inhibitor-induced hemorrhage could be found in the preclinical or clinical literature.^{21,22}

DISCUSSION

Because of tPA-associated orolingual angioedema's rarity, no targeted treatment exists for it. Symptomatic management with supportive care, corticosteroids, epinephrine, and histamine antagonists is considered first-line therapy.^{3-5,7,9} Rapid progression with airway compromise and pending asphyxia may occur despite these treatments.^{5,7} Food and Drug Administration–approved therapies for hereditary angioedema that antagonize bradykinin or target the kallikrein-kinin system are believed to treat severe drug-induced angioedema because of the similarities in disease pathophysiology.^{1,15-18,20} Bradykinin B2 antagonist and the plasma-derived C1 esterase inhibitor have been successfully used in the treatment of angiotensin-converting enzyme inhibitor–related angioedema in case reports and case series.¹⁷⁻²⁰ Plasma-derived C1 esterase inhibitor was used in this case because of its availability. The ecallantide supply was patient specific and was unable to be used, whereas icatibant was unavailable at the time. To our knowledge, there are no data available to indicate superiority for any of these therapies for pharmacologic-induced orolingual angioedema, including tPA-induced cases.

C1 esterase inhibitor is a protein that acts on the complement system by inactivating the esterase activity of C1, resulting in cessation of complement activation. C1 esterase inhibitor also regulates the cascade through activated factor XII (XIIa) and kallikrein inhibition, with additional inhibition of activated factor XI (XIa), plasmin, and tPA.^{1,15} Inhibition of kallikrein and factor XIIa prevents bradykinin release, which should attenuate development of orolingual angioedema.

Patients with airway compromise caused by orolingual angioedema and recent administration of tPA may be at risk for additional complications. Pharmacologic interventions may be necessary to treat this potentially life-threatening complication of tPA therapy. The use of a C1 esterase inhibitor may have been temporally related to expedited resolution of the severe orolingual angioedema observed in this case. Previous literature suggests that it may take up to 36 hours to achieve resolution of symptoms.⁵ C1 esterase inhibitor may serve as a treatment option to avoid invasive procedures, although cost and availability may prohibit their use. Many institutions do not maintain supply of this therapy, so other methods to manage tPA-induced orolingual angioedema may be necessary.

Conclusion

There are no first-line treatment recommendations for orolingual angioedema caused by tPA administration, but standard anaphylaxis treatment can be used to relieve or contain progressive or worsening edema.⁴ Many patients have resolution of symptoms with supportive care, corticosteroids, epinephrine, and histamine antagonists; however, there can be rapid progression and asphyxia in those who develop angioedema.^{6,16} It is important to be aware of other pharmacologic treatment options if tPA-induced orolingual angioedema leads to severe airway obstruction, necessitating the need for an emergency airway. C1 esterase inhibitor may be an additional therapeutic option for patients presenting with tPA-induced orolingual angioedema with potential airway compromise that is refractory to standard of care.

The authors acknowledge Opeolu Adeoye, MD, MS, and Shaun Keegan, PharmD, for their involvement in the direct care of the patient and their review of the final manuscript.

Supervising editors: William J. Meurer, MD, MS; Donald M. Yealy, MD

Author affiliations: From the University of Cincinnati Medical Center, Cincinnati, OH (Pahs, Droege, Pancioli); and the St. John Medical Center, Tulsa, OK (Kneale).

Funding and support: By *Annals* policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). The authors have stated that no such relationships exist.

REFERENCES

- Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. *J Allergy Clin Immunol*. 2002;109:195-209.
- Walford HH, Zuraw BL. Current update on cellular and molecular mechanisms of hereditary angioedema. *Ann Allergy Asthma Immunol*. 2014;112:413-418.
- Gorski EM, Schmidt MJ. Orolingual angioedema with alteplase administration for treatment of acute ischemic stroke. *J Emerg Med*. 2013;45:e25-26.
- Miller DJ, Simpson JR, Silver B. Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies. *Neurohospitalist*. 2011;1:138-147.
- Ottomeyer C, Hennerici MG, Szabo K. Raising awareness of orolingual angioedema as a complication of thrombolysis in acute stroke patients. *Cerebrovasc Dis*. 2009;27:307-308.
- Engelter ST, Fluri F, Buitrago-Tellez C, et al. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. *J Neurol*. 2005;252:1167-1170.
- Fugate JE, Kalimullah EA, Wijedicks EF. Angioedema after tPA: what neurointensivists should know. *Neurocrit Care*. 2012;16:440-443.
- Rafii MS, Koenig M, Ziai WC. Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke. *Neurology*. 2005;65:1906.
- Zarar A, Khan AA, Adil MM, et al. Anaphylactic shock associated with intravenous thrombolytics. *Am J Emerg Med*. 2014;32:113.e3-5.
- Werner R, Keller M, Woehrl JC. Facial angioedema and stroke. *Cerebrovasc Dis*. 2014;38:101-106.
- Hill MD, Lye T, Barber PA, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. *Neurology*. 2003;60:1525-1527.
- Pancioli A, Brott T, Donaldson V, et al. Asymmetric angioneurotic edema associated with thrombolysis for acute stroke. *Ann Emerg Med*. 1997;30:227-229.
- Maertins M, Wold R, Swider M. Angioedema after administration of rtPA for ischemic stroke: a case report. *Air Med J*. 2011;30:276-278.
- Dromerick AW, Meschia JF, Kumar A, et al. Simultaneous bilateral thalamic hemorrhages following the administration of intravenous tissue plasminogen activator. *Arch Phys Med Rehabil*. 1997;78:92-94.
- Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. *Ann Emerg Med*. 2010;56:278-282.
- Ismail S, Cheng L, Grigoriadou S, et al. Lesson of the month 2: the limitations of steroid therapy in bradykinin-mediated angioedema attacks. *Clin Med*. 2015;15:101-103.
- Lipski SM, Casimir G, Vanlommel M, et al. Angiotensin-converting enzyme inhibitors-induced angioedema treated by C1 esterase inhibitor concentrate (Berinert®): about one case and review of the therapeutic arsenal. *Clin Case Rep*. 2015;3:126-130.
- Bova M, Guilarte M, Sala-Cunill A, et al. Treatment of ACEI-related angioedema with icatibant: a case series. *Intern Emerg Med*. 2015;10:345-350.
- Bas M, Greve J, Steiter K, et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. *N Engl J Med*. 2015;372:418-425.
- Strassen U, Bas M, Hoffmann TK, et al. Treatment of angiotensin receptor blocker-induced angioedema: a case series. *Laryngoscope*. 2015;125:1619-1623.
- Crowther M, Bauer KA, Kaplan AP. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. *Allergy Asthma Proc*. 2014;35:444-453.
- Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. *Pharmacotherapy*. 2012;32:902-909.